Ipamorelin vs Sermorelin 2026: Which GH Peptide Wins?
Both peptides stimulate your pituitary gland to release growth hormone. But they work through different receptors, peak at different speeds, and suit different patients. Here is a direct comparison based on the pharmacology, not marketing.
In this article
Key Takeaways
- Ipamorelin is a ghrelin receptor agonist (GH secretagogue). Sermorelin is a GHRH analog. They stimulate growth hormone through two different pituitary receptors.
- Ipamorelin is highly selective. It does not raise cortisol or prolactin. Sermorelin can produce mild flushing and headaches in some patients.
- Sermorelin was FDA-approved in the 1990s (commercially discontinued). Ipamorelin has never been FDA-approved and is available through compounding pharmacies.
- Sermorelin peaks faster (about 15 minutes). Ipamorelin peaks at 30-45 minutes. Both are subcutaneous injection, typically at bedtime to align with natural GH rhythm.
- Most providers do not stack Sermorelin and Ipamorelin (redundant GHRH signaling). The dominant protocol is CJC-1295/Ipamorelin, which pairs Ipamorelin with a longer-acting GHRH analog.
Quick Facts
Ipamorelin Type
Growth hormone secretagogue (GHSR agonist)
Sermorelin Type
Growth hormone-releasing hormone (GHRH analog)
FDA History
Sermorelin was FDA-approved (1990s, discontinued commercially). Ipamorelin has not been FDA-approved.
Selectivity
Ipamorelin is more selective — does not raise cortisol or prolactin
Common Pairing
Ipamorelin is almost always paired with CJC-1295
Onset
Sermorelin peaks faster (~15 min). Ipamorelin peaks in ~30-45 min.
The Quick Comparison
| Ipamorelin | Sermorelin | ||
|---|---|---|---|
| Class | Class | GH secretagogue (ghrelin receptor) | GHRH analog (GHRH receptor) |
| Mechanism | Mechanism | Mimics ghrelin signaling at the pituitary | Mimics natural GHRH at the pituitary |
| GH Release | GH Release Pattern | Clean pulse, selective | Broader pulse, mimics natural rhythm |
| Cortisol | Raises Cortisol? | No | Minimal |
| Prolactin | Raises Prolactin? | No | Minimal |
| Side Effects | Common Side Effects | Injection site irritation, mild headache | Flushing, headache, injection site irritation |
| FDA | FDA History | Never FDA-approved | FDA-approved 1990s (discontinued) |
| Typical Use | Typical Use | Paired with CJC-1295 for sustained GH | Used alone or with GHRP |
| Cost | Monthly Cost (PeRx) | $229-$279 (as CJC-1295/Ipamorelin) | $199-$249 |
How Each One Works
Your pituitary gland releases growth hormone in pulses throughout the day, with the largest pulse during deep sleep. Two signals control this release: GHRH (growth hormone-releasing hormone) tells the pituitary to fire, and ghrelin (from the stomach) amplifies the signal. Sermorelin and Ipamorelin target different sides of this system.
Sermorelin: the GHRH mimic
Sermorelin is a 29-amino-acid analog of your natural GHRH. It binds to the same GHRH receptor on the pituitary and triggers GH release through the same pathway your hypothalamus uses. The result is a GH pulse that looks very similar to your natural pattern. Sermorelin was FDA-approved in the 1990s under the brand name Geref for diagnosing and treating growth hormone deficiency in children. It was voluntarily discontinued by the manufacturer for commercial reasons, not safety concerns.
Ipamorelin: the ghrelin mimic
Ipamorelin is a pentapeptide (5 amino acids) that binds to the ghrelin receptor (GHSR) on the pituitary. It stimulates GH release through a different pathway than Sermorelin. What makes Ipamorelin unusual is its selectivity. Most ghrelin-pathway secretagogues (like GHRP-6 or GHRP-2) also increase cortisol, prolactin, and appetite. Ipamorelin does not. It triggers a clean GH pulse without the hormonal noise.
This selectivity is why Ipamorelin became the preferred secretagogue in clinical practice. You get the GH release without the cortisol spike (which promotes fat storage and disrupts sleep) or the prolactin increase (which can cause water retention and other issues at elevated levels).
Side Effects
Both peptides are well-tolerated. The most common side effect for either is mild injection site irritation. Beyond that, the profiles diverge slightly.
Sermorelin can cause facial flushing (a warm, red sensation in the face) shortly after injection, particularly at higher doses. Some patients report headaches. These effects are related to the broader hormonal response that GHRH signaling triggers.
Ipamorelin rarely causes flushing. Headaches are occasionally reported during the first week. Because it does not increase cortisol or prolactin, the downstream side effects associated with those hormones (water retention, mood changes, appetite spikes) are absent.
Both peptides can cause temporary water retention and hand tingling during the first 1 to 2 weeks as GH levels rise. This resolves as the body adjusts.
Who Should Use Which
Ideal for
Sermorelin may be the better fit if: - You want the most natural GH signaling pattern possible - You prefer a peptide with FDA approval history and decades of clinical use - You are cost-sensitive ($199-$249/mo vs $229-$279/mo for CJC/Ipa) - You are new to peptide therapy and want a conservative starting point - You are primarily focused on sleep quality and general anti-aging
Consider alternatives if
CJC-1295/Ipamorelin may be the better fit if: - You want the strongest GH response with the cleanest side effect profile - You are focused on body composition (fat loss + lean muscle) - You have had flushing or headaches with Sermorelin previously - You want sustained GH elevation (CJC-1295 extends the GH pulse for hours) - You are an athlete focused on recovery and performance
Why CJC-1295/Ipamorelin Became the Standard
Ipamorelin is rarely prescribed alone. Almost every protocol pairs it with CJC-1295, and there is a good pharmacological reason for this.
Ipamorelin triggers a sharp GH pulse, but it is short-lived. CJC-1295 is a GHRH analog (like Sermorelin) but with a modification called Drug Affinity Complex (DAC) that extends its half-life from minutes to days. When you combine the two, CJC-1295 provides a sustained baseline elevation of GH signaling, and Ipamorelin adds a clean, sharp pulse on top of it. The result is higher overall GH output than either peptide alone.
This is why CJC-1295/Ipamorelin has become the most commonly prescribed growth hormone peptide combination in telehealth. It attacks GH release from two angles simultaneously: the GHRH pathway (CJC-1295) and the ghrelin pathway (Ipamorelin).
Bottom Line
Sermorelin is the simpler, more affordable option with a strong safety track record. CJC-1295/Ipamorelin is the more potent combination with a cleaner side effect profile. Neither is wrong. The choice depends on your goals, budget, and how aggressively you want to optimize GH output.
Frequently Asked Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
Sermorelin: FDA-Approved 1997-2008 (2026 Status)
Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.
Sermorelin 2026: The Original Growth Hormone Peptide
Every growth hormone peptide used today traces its lineage back to this molecule. Sermorelin was once FDA-approved, then abandoned for commercial reasons. Now it's having a second act as the safest entry point into growth hormone optimization. The peptide that was too gentle for children turned out to be exactly what adults needed.
Pinealon, PE-22-28 & Selank Guide (2026)
Three peptides, three layers of brain support. Pinealon restores sleep architecture through pineal gland regulation. PE-22-28 drives neurogenesis by blocking the TREK-1 potassium channel. Selank calms anxiety through GABA modulation without sedation or dependence. Together they rebuild, grow, and protect neural tissue from three independent angles.
Ready to get started?
Sermorelin and CJC-1295/Ipamorelin are both available through PeRx with a licensed provider prescription.
Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.